

**KESIMPTA
(ofatumumab)**

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age and older

Diagnosis

Patient must have the following:

1. Relapsing Multiple Sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease

AND ALL of the following:

1. Patient is not at risk for HBV infection **OR** patient is at risk for HBV infection and HBV infection has been ruled out or treatment for HBV infection has been initiated
2. Absence of active infection
3. Prescriber agrees to monitor immunoglobulins at the beginning, during and after discontinuation of therapy
4. **NOT** used in combination with another MS disease-modifying agent
5. **NOT** used in combination with other immune-modulating or immunosuppressive therapies, including immunosuppressant doses of corticosteroids
6. **NOT** given concurrently with live vaccines or live-attenuated vaccines

Prior - Approval Limits

Duration 2 years

Prior – Approval *Renewal* Requirements

Age 18 years of age and older

Diagnosis

Patient must have the following:



**BlueCross
BlueShield**

Federal Employee Program.

**KESIMPTA
(ofatumumab)**

1. Relapsing Multiple Sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease

AND ALL of the following:

1. Absence of active infection
2. Prescriber agrees to monitor immunoglobulins during and after discontinuation of therapy
3. **NOT** used in combination with another MS disease-modifying agent
4. **NOT** used in combination with other immune-modulating or immunosuppressive therapies, including immunosuppressant doses of corticosteroids
5. **NOT** given concurrently with live vaccines or live-attenuated vaccines

Prior - Approval *Renewal* Limits

Same as above